Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.50 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.50 |
| ▸ | MAPKAPK2 | P49137 | 5/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31584465 | 0.78 | MAPKAPK2 (0.43) | STK17BSTK17AMAPKAPK2KDM4AL3MBTL1 | |
| SCHEMBL18878472 | 0.76 | LMNA (0.51) | MAPKAPK2KDM4ALMNA | |
| SCHEMBL19782553 | 0.76 | ATR (0.47) | STK17BSTK17AMAPKAPK2KDM4APOLB | |
| SCHEMBL30162902 | 0.75 | AAK1 (0.45) | STK17BSTK17AMAPKAPK2KDM4APOLB | |
| SCHEMBL16809853 | 0.75 | AAK1 (0.45) | STK17BSTK17AMAPKAPK2KDM4APOLB | |
| SCHEMBL21555712 | 0.75 | STK17B (0.44) | STK17BSTK17AMAPKAPK2KDM4APOLB | |
| SCHEMBL30670723 | 0.73 | STK17B (0.47) | STK17BSTK17AMAPKAPK2KDM4APOLB | |
| SCHEMBL26657670 | 0.73 | STK17B (0.47) | STK17BSTK17AMAPKAPK2KDM4APOLB | |
| SCHEMBL31704902 | 0.73 | CYP1A2 (0.50) | MAPK1L3MBTL1 | |
| SCHEMBL1585183 | 0.73 | STK17B (0.52) | STK17BSTK17AMAPKAPK2KDM4APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| EP-4240736-A1 | PPAR GAMMA MODULATORS AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2023-09-13 | — | — | EP | disclosed |
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-03-02 | — | — | US | disclosed |
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-03-02 | — | — | US | disclosed |
| WO-2022099144-A1 | ΡΡΑRγ MODULATORS AND METHODS OF USE | Eisai R&D Mangement Co., Ltd. (JP) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022099144-A1 | ΡΡΑRγ MODULATORS AND METHODS OF USE | Eisai R&D Mangement Co., Ltd. (JP) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | PPARG, PPARA, PPARD | STK17B 2052/4885STK17A 2068/4885MAPKAPK2 1300/4885 |
| US-12606541-B2 | PPARg modulators and methods of use | PPARG, PPARA, PPARD | STK17B 3299/4885STK17A 3387/4885MAPKAPK2 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.